Market Access News | pharmaphorum

News

Vydura is NHS’ first oral CGRP for migraine prevention

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this ye

News

Iovance eyes November FDA decision on melanoma cell therapy

Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U

News

SGLT latecomer Lexicon gets heart failure okay

Lexicon Pharma tried and failed to get FDA approval for its SGLT inhibitor sotagliflozin for diabetes, but it has finally got the drug over the finish line – for a differe

News

EU approval for Novartis’ sickle cell drug set to be pulled

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy

News

CMS plan would shine light on Medicaid drug pricing

A proposal by the US Department of Health and Human Services (HHS) would expose the actual costs of drugs covered by Medicaid, and hold manufacturers to account for the am

News

Innoviva gets FDA nod for pneumonia antibiotic

The FDA has given a green light to Innoviva’s antibiotic combination Xacduro, which becomes the first drug specifically approved for pneumonia caused by hard-to-treat bact

Vydura is NHS’ first oral CGRP for migraine prevention

Iovance eyes November FDA decision on melanoma cell therapy

SGLT latecomer Lexicon gets heart failure okay

EU approval for Novartis’ sickle cell drug set to be pulled

CMS plan would shine light on Medicaid drug pricing

Innoviva gets FDA nod for pneumonia antibiotic

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks